Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

• Status: Completed
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: All

Summary

A phase 2, multicenter, randomized, active-controlled, masked, parallel arm study designed to evaluate the safety and efficacy of a single suprachoroidal injection of CLS-TA, triamcinolone acetonide injectable suspension, given along with an intravitreal (IVT) injection of aflibercept compared to IVT aflibercept alone in subjects with retinal vein occlusion (RVO).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Clearside Biomedical, Inc.
• Treatments: Aflibercept; Polystyrene sulfonic acid; Triamcinolone Acetonide

Criteria

Inclusion Criteria:

• diagnosis of macular edema following RVO

• History of ME ≤ 12 months

• 20-70 letters inclusive BCVA using ETDRS

Exclusion Criteria:

• has had an IVT injection of anti-VEGF for RVO in the study eye

• has had a corticosteroid injection in the past 3 months in the study eye

• any uncontrolled ophthalmic condition in the study eye other than RVO